Прогнозирование сердечно-сосудистых событий: расширение показаний к применению высокочувствительного теста на тропонин I

1. Passimo C, Almo A, Masotti S, et al. Cardiac troponins as biomarkers for cardiac disease. Biomark Med. 2019;13(5):325-30.
2. Perry SV. Troponin I: inhibitor or facilitator. Moll Cell Biochem. 1999;190(1-2):9-32.
3. Kachooei E, Cordina NM, Potluri PR, et al. Prosphorylation of troponin I finely controls the positioning of troponin for the optimal regulation of cardiac muscle contraction. J Moll Cell Cardiol. 2021;150:44-53.
4. Ni CY. Cardiac troponin I: a biomarker for detection and risk stratification of minor myocardial damage. Clin Lab. 2001;47(9-10):483-92. 
5. Katrukha IA, Katrukha AG. Myocardial injury and the release of troponin I and in blood of patients. Clin Chem. 2021;67(1):124-30.
6. Sandoval Y, Nowak R, deFilippi CR, et al. Myocardial infarction risk stratification with a single management of high-sensitivity troponin I. J Am Coll Cardiol. 2019;74(3):271-82.
7. Chapman AR, Lee KK, McAllister DA, et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA. 2017;318(19):1913-24. 
8. Ebner M, Guddat N, Keller K, et al. High-sensitivity troponin I in risk stratification in normotensive pulmonary embolism. ERJ Open Res. 2020;6(4):00625-2020.
9. Farmakis D, Mueller C, Apple FS. High sensitivity cardiac troponin I assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020;40(41):4050-6.
10. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac troponin I management for risk stratification in stable high-risk population. Clin Chem. 2011;57(8):1146-53.
11. Ran NSR, Bell DA, McCaul KA, et al. High sensitivity cardiac troponin I improves cardiovascular risk prediction in older men: HIMS (The Health In Men Study). J Am Heart Assoc. 2019;8(5):e011818.
12. Yiu KH, Lau KK, Zhao CT, et al. Predictive value of high-sensitivity troponin-I for future adverse events cardiovascular outcomes in stable patients with type 2 diabetes mellitus. Cardiovasular Dabetol. 2014;13:63.
13. Tahhan AS, Sandesara P, Hayek SS, et al. High-sensitivity troponin I levels and coronary arteries disease severity, progression, and long-term outcomes. J Am Heart Assoc. 2018;7(5):e007914.
14. Omland T, Pfeffer MA, Solomon SD, for PEACE Investigators. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61:1240-9.
15. Eisen A, Bonaca MP, Jarolim P, et al. High-sensitivity troponin I in stable patients with atherosclerotic disease in TRA 2oP TIMI trial. Clin Chem. 2017;63(1):307-15.
16. Adamson PD, Hunter A, Madsen DM, et al. High sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227. 
17. Januzzi JL, Suchindran S, Coles A, et al. on behalf on PROMISE Investigators. High sensitivity troponin I and coronary computed tomography in symptomatic patients with suspected CAD. Insights from the PROMISE Trial. JACC Cardiovasc Imag. 2019;12(6):1047-55.
18. Hromadka M, Seidlerova J, Baxa J, et al. Relationship between hsTnI and coronary stenosis in asymptomatic women with rheumatoid arthritis. BMC Cardiovasc Disord. 2016;16(1):184.
19. Ford I, Shah ASV, Zhang R, et al. High sensitivity cardiac troponin, statin therapy and risk of coronary heart disease. J Am Coll Cardiol. 2016;68(25):2719-28.
20. Everett BM, Zeller T, Glynn RJ, et al. High sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention. Impact of statin therapy. Circulation. 2015;131:1851-60.
21. Blankenberg S, Salomaa V, Makarova N, et al. for BiomarCaRe Investigators. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRe consortium. Eur Heart J. 2016;37(30):2428-37.
22. Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Reactive prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-Trondelag Health (HUNT) Study). Am J Cardiol. 2018;121:949-51.
23. Lyngbakken ML, Rosjo H, Holmen OL, et al. Events in the general population: Nord-Trondelag Health Study. Clin Chem. 2019;65(7):871-81.
24. Olson F, Engborg J, Gronhoj MH, et al. Association between high-sensitive troponin I and coronary artery calcification in Danish general population. Atherosclerosis. 2016;245:88-93.
25. Tang O, Matsushita K, Coresh J, et al. High-sensitivity cardiac troponin I and T for cardiovascular risk stratification in adults with diabetes. Daibetes Care. 2020;43:e144-6.
26. Jagodzinski A, Neumann JT, Ojeda F, et al. Cardiovascular biomarkers in hypertensive patients with medical treatment – results from the randomized TEAMSTA Protect I Trial. Clin Chem. 2017;63(12):1877-85.
27. Jülicher P, Varounis C. Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I. Eur Heart J. 2022;8(3):342-51. DOI:10.1093/ehjqcco/qcab005 
28. Jülicher P, Makarova N, Ojeda F, et al. Costeffectiveness of applying high-sensitivity troponin I to a score for cardiovascular risk prediction in asymptomatic population. PLoS ONE. 2024;19(7):e0307468. DOI:10.1371/journal
29. Watanabe N, Noh JY, Hattori N, et al. Cardiac troponin is elevated in patients with thyrotoxicosis and decreases as thyroid function improves and brain natriuretic peptide levels decrease. Eur Thyroid J. 2020;10(6):468-75.
30. Wu X, Deng KQ, Li C, et al. Cardiac involvement in recovered patients form COVID-19: a preliminary 6-month follow-up study. Front Cardiovasc Med. 2021;13(8):654405.
31. Maino A, Di Stasio E, Grimaldi MC, et al. Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin. Int J Cardiol. 2021;338(4):278-85. DOI:10.1016/j.ijcard.2021.06.028
32. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J Cardiovasc Imag. 2022;10:e333-465.
33. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43(39):3826-924.
34. Драпкина О.М., Шальнова С.А., Концевая А.В., и др. Прогностическая значимость тропонина I в оценке сердечно-сосудистого риска в российской популяции. По результатам многоцентровых исследований ЭССЕ-РФ1 и ЭССЕ-РФ2. Кардиоваскулярная терапия и профилактика. 2023;22(5):3548 [Drapkina OM, Shalnova SA, Kontsevaya AV, et al. Prognostic significance of troponin I in assessing cardiovascular risk in the Russian population. Data from ESSE-RF1 and ESSE-RF2 multicenter studies. Cardiovascular Therapy and Prevention. 2023;22(5):3548 (in Russian)]. DOI:10.15829/1728-8800-2023-3548

________________________________________________

1. Passimo C, Almo A, Masotti S, et al. Cardiac troponins as biomarkers for cardiac disease. Biomark Med. 2019;13(5):325-30.
2. Perry SV. Troponin I: inhibitor or facilitator. Moll Cell Biochem. 1999;190(1-2):9-32.
3. Kachooei E, Cordina NM, Potluri PR, et al. Prosphorylation of troponin I finely controls the positioning of troponin for the optimal regulation of cardiac muscle contraction. J Moll Cell Cardiol. 2021;150:44-53.
4. Ni CY. Cardiac troponin I: a biomarker for detection and risk stratification of minor myocardial damage. Clin Lab. 2001;47(9-10):483-92. 
5. Katrukha IA, Katrukha AG. Myocardial injury and the release of troponin I and in blood of patients. Clin Chem. 2021;67(1):124-30.
6. Sandoval Y, Nowak R, deFilippi CR, et al. Myocardial infarction risk stratification with a single management of high-sensitivity troponin I. J Am Coll Cardiol. 2019;74(3):271-82.
7. Chapman AR, Lee KK, McAllister DA, et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA. 2017;318(19):1913-24. 
8. Ebner M, Guddat N, Keller K, et al. High-sensitivity troponin I in risk stratification in normotensive pulmonary embolism. ERJ Open Res. 2020;6(4):00625-2020.
9. Farmakis D, Mueller C, Apple FS. High sensitivity cardiac troponin I assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020;40(41):4050-6.
10. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac troponin I management for risk stratification in stable high-risk population. Clin Chem. 2011;57(8):1146-53.
11. Ran NSR, Bell DA, McCaul KA, et al. High sensitivity cardiac troponin I improves cardiovascular risk prediction in older men: HIMS (The Health In Men Study). J Am Heart Assoc. 2019;8(5):e011818.
12. Yiu KH, Lau KK, Zhao CT, et al. Predictive value of high-sensitivity troponin-I for future adverse events cardiovascular outcomes in stable patients with type 2 diabetes mellitus. Cardiovasular Dabetol. 2014;13:63.
13. Tahhan AS, Sandesara P, Hayek SS, et al. High-sensitivity troponin I levels and coronary arteries disease severity, progression, and long-term outcomes. J Am Heart Assoc. 2018;7(5):e007914.
14. Omland T, Pfeffer MA, Solomon SD, for PEACE Investigators. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61:1240-9.
15. Eisen A, Bonaca MP, Jarolim P, et al. High-sensitivity troponin I in stable patients with atherosclerotic disease in TRA 2oP TIMI trial. Clin Chem. 2017;63(1):307-15.
16. Adamson PD, Hunter A, Madsen DM, et al. High sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227. 
17. Januzzi JL, Suchindran S, Coles A, et al. on behalf on PROMISE Investigators. High sensitivity troponin I and coronary computed tomography in symptomatic patients with suspected CAD. Insights from the PROMISE Trial. JACC Cardiovasc Imag. 2019;12(6):1047-55.
18. Hromadka M, Seidlerova J, Baxa J, et al. Relationship between hsTnI and coronary stenosis in asymptomatic women with rheumatoid arthritis. BMC Cardiovasc Disord. 2016;16(1):184.
19. Ford I, Shah ASV, Zhang R, et al. High sensitivity cardiac troponin, statin therapy and risk of coronary heart disease. J Am Coll Cardiol. 2016;68(25):2719-28.
20. Everett BM, Zeller T, Glynn RJ, et al. High sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention. Impact of statin therapy. Circulation. 2015;131:1851-60.
21. Blankenberg S, Salomaa V, Makarova N, et al. for BiomarCaRe Investigators. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRe consortium. Eur Heart J. 2016;37(30):2428-37.
22. Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Reactive prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-Trondelag Health (HUNT) Study). Am J Cardiol. 2018;121:949-51.
23. Lyngbakken ML, Rosjo H, Holmen OL, et al. Events in the general population: Nord-Trondelag Health Study. Clin Chem. 2019;65(7):871-81.
24. Olson F, Engborg J, Gronhoj MH, et al. Association between high-sensitive troponin I and coronary artery calcification in Danish general population. Atherosclerosis. 2016;245:88-93.
25. Tang O, Matsushita K, Coresh J, et al. High-sensitivity cardiac troponin I and T for cardiovascular risk stratification in adults with diabetes. Daibetes Care. 2020;43:e144-6.
26. Jagodzinski A, Neumann JT, Ojeda F, et al. Cardiovascular biomarkers in hypertensive patients with medical treatment – results from the randomized TEAMSTA Protect I Trial. Clin Chem. 2017;63(12):1877-85.
27. Jülicher P, Varounis C. Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I. Eur Heart J. 2022;8(3):342-51. DOI:10.1093/ehjqcco/qcab005 
28. Jülicher P, Makarova N, Ojeda F, et al. Costeffectiveness of applying high-sensitivity troponin I to a score for cardiovascular risk prediction in asymptomatic population. PLoS ONE. 2024;19(7):e0307468. DOI:10.1371/journal
29. Watanabe N, Noh JY, Hattori N, et al. Cardiac troponin is elevated in patients with thyrotoxicosis and decreases as thyroid function improves and brain natriuretic peptide levels decrease. Eur Thyroid J. 2020;10(6):468-75.
30. Wu X, Deng KQ, Li C, et al. Cardiac involvement in recovered patients form COVID-19: a preliminary 6-month follow-up study. Front Cardiovasc Med. 2021;13(8):654405.
31. Maino A, Di Stasio E, Grimaldi MC, et al. Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin. Int J Cardiol. 2021;338(4):278-85. DOI:10.1016/j.ijcard.2021.06.028
32. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J Cardiovasc Imag. 2022;10:e333-465.
33. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43(39):3826-924.
34. Drapkina OM, Shalnova SA, Kontsevaya AV, et al. Prognostic significance of troponin I in assessing cardiovascular risk in the Russian population. Data from ESSE-RF1 and ESSE-RF2 multicenter studies. Cardiovascular Therapy and Prevention. 2023;22(5):3548 (in Russian). DOI:10.15829/1728-8800-2023-3548

В.В. Фомин* 

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*fomin_v_v_1@staff.sechenov.ru

________________________________________________

Victor V. Fomin*

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*fomin_v_v_1@staff.sechenov.ru